Funding for this research was provided by:
European Headache Federation
Received: 22 July 2018
Accepted: 20 September 2018
First Online: 26 September 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: LB: Scientific advisory board for Novartis, Allergan and Biogen, principal investigator for Biogen and lectures for Allergan, Novartis and Teva. SS: Scientific advisory board for Allergan, Bayer Healthcare, Medtronic. MA: Personal fees from Alder BioPharmaceuticals, Allergan, Amgen, Alder, Eli Lilly, Novartis and Teva. Participated in clinical trials as the principal investigator for Alder ALD403-CLIN-011 (Phase 3b), Amgen 20,120,178 (Phase 2), 20,120,295 (Phase 2), 20,130,255 (OLE), 20,120,297 (Phase 3), GM-11 gamma-Core-R trials, Novartis CAMG334a2301 (Phase 3b), Amgen PAC1 20,150,308 (Phase 2a), Teva TV48125-CNS-30068 (Phase 3). Serves as associated editor of Cephalalgia, co-editor of the Journal of Headache and Pain.DM: Scientific advisory board for Novartis, Eli Lilly, Sanofi-Genzyme and Teva. Principal investigator for Biogen, Cephaly, Genesis Pharma, Merck-Serono, Merz, Novartis and Teva. Has received honoraria for lecturing from Allergan, Amgen, Cephaly, Biogen, Genesis Pharma, Novartis, Rosche, Sanofi-Genzyme, Teva. FA: Consultant for Novartis, Allergan, Eneura and Electrocore (honorarium paid to the British Association for the Study of Headache and the Migraine Trust). PPR: Consultant and speaker for Allergan, Almirall, Chiesi, Eli Lilly, Novartis and Teva. Her research group has received research grants from Allergan and Novartis and has received funding for clinical trials from Alder, Boeringher Ingelheim, MSD, Electrocore, Eli Lilly, Janssen Cilag, Novartis and Teva. PM: Scientific Advisory Board for Allergan, Amgen, Electrocore, Eli Lilly, Novartis, Springer HealthCare, Teva.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.